Pictet Asset Management
MYGN icon

Pictet Asset Management’s Myriad Genetics MYGN Stock Holding History

Pictet Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.5K Hold
13,224
– – ﹤0.01% 2078
2025
Q4 		$81.3K Hold
13,224
– – ﹤0.01% 2044
2025
Q3 		$95.6K Hold
13,224
– – ﹤0.01% 1984
2025
Q2 		$70.2K Hold
13,224
– – ﹤0.01% 1973
2025
Q1 		$117K Sell
13,224
-466,584
-97% -$5.6M ﹤0.01% 1901
2024
Q4 		$6.58M Sell
479,808
-36,262
-7% -$669K 0.01% 759
2024
Q3 		$13.7M Sell
516,070
-27,418
-5% -$742K 0.02% 577
2024
Q2 		$13.3M Sell
543,488
-670,828
-55% -$14.7M 0.02% 572
2024
Q1 		$25.9M Sell
1,214,316
-80,458
-6% -$1.73M 0.03% 429
2023
Q4 		$24.8M Buy
1,294,774
+76,528
+6% +$1.32M 0.03% 427
2023
Q3 		$19.5M Buy
+1,218,246
New +$23.2M 0.02% 465

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pictet Asset Management's MYGN Position: Q1 2026 in Review

Pictet Asset Management held its Myriad Genetics (MYGN) position steady in Q1 2026 at 13,224 shares worth $59.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2078.

Pictet Asset Management first reported a position in MYGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $25.9M in Q1 2024. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Pictet Asset Management held 13,224 shares of Myriad Genetics worth $59.5K as of Q1 2026.
  • Pictet Asset Management left its Myriad Genetics share count unchanged in Q1 2026.
  • Myriad Genetics made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #2078 holding.
  • Pictet Asset Management first reported a position in Myriad Genetics in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Myriad Genetics position peaked at $25.9M in Q1 2024.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.